Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Sanofi's $595m Singapore facility, Modulus, leverages advanced technology for rapid, flexible vaccine production, bolstering ...

The 58,000 sq m plant – Sanofi’s second factory in Singapore – will produce vaccines and other biopharmaceutical products ...

Sanofi inaugurated its $800m healthcare manufacturing facility, Modulus, located in Tuas Biomedical Park to be operational in ...

The global small-molecule injectable market is poised for significant growth, with an estimated valuation of USD 65.10 ...

Expansion into Emerging Markets with High Prevalence of Chronic Inflammatory Conditions Presenting Lucrative Opportunities ...

Clinical trials for a revolutionary vaccine to treat acne will be conducted by the National Skin Centre in partnership with ...

The biggest threat for European pharmaceutical groups currently comes from the United States. President-elect Donald Trump ...

Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

The collaboration includes a phase 1 clinical study to start in the second quarter of 2025. The National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) ...

Prime Minister Pham Minh Chinh on November 28 received visiting Minister-President of Germany’s State of Hesse Boris Rhein, ...

Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet ...